CEACAM5 and cancer: In patients with Dukes' stage B cancer, significant differences in OS and DFS were not seen between those who were positive for CEA/CK and those who were negative for CEA/CK (Fig. 3), nor were significant differences found between patients who were positive for CD133 as compared with those who were negative for CD133 (Fig. 4).